Highest-materiality recent filing
Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M
Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.
Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO
Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.
Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire
Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.
Absci to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference
Absci will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs
Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.
Absci resolves Totient merger milestone payments; receives $8.7M, pays $7.6M
Executed Letter Agreement with SBGH to distribute $16.3M escrow funds from 2021 Totient merger.
Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands
Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.
Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).
Absci prices $50M public offering of 16.67M shares at $3.00 per share
Offering of 16,670,000 shares at $3.00 per share; gross proceeds ~$50M.
Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option
Mary Szela appointed as Class III director; board expanded from six to seven members.
Absci stockholders elect van Houten and McGinnis to board, ratify EY as auditor
Frans van Houten elected with 51.4M votes for, 15.7M withheld, 26.1M broker non-votes.
Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027
Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.
Absci director Amrit Nagpal resigns from board effective April 25, 2025
Amrit Nagpal resigned from Absci's Board of Directors and all committees effective April 25, 2025.
Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration
Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.
Absci announces J.P. Morgan Healthcare Conference presentation; slides contain no new business data
Presentation at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.
Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.
Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.
Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab
Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).
Absci stockholders elect three Class III directors and ratify EY as auditor at annual meeting
Sean McClain, Amrit Nagpal, and Joseph Sirosh elected Class III directors for terms until 2027 annual meeting.
Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies
Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.
Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M
FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.
On April 25, 2025, Amrit Nagpal notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of April 25, 2025.
Max materiality 0.80 · Median 0.70 · Most common event earnings